Nurix Therapeutics, Inc.
NRIX · NASDAQ
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.23 | 0.54 | -0.62 |
| FCF Yield | -7.65% | -7.38% | -5.00% | -2.93% |
| EV / EBITDA | -9.38 | -18.65 | -20.52 | -26.05 |
| Quality | ||||
| ROIC | -20.59% | -9.44% | -11.82% | -11.12% |
| Gross Margin | 36.66% | -77.27% | -277.52% | -406.05% |
| Cash Conversion Ratio | 0.66 | 1.45 | 1.08 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.85% | 13.20% | 10.61% | 12.19% |
| Free Cash Flow Growth | 8.72% | -1.96% | -26.97% | -14.22% |
| Safety | ||||
| Net Debt / EBITDA | 0.27 | 0.70 | 0.81 | 1.29 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -135.58 | 31.95 | 33.53 | -5.21 |